The injection is expected to be available by late August 2026 in the US.

FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer’s disease ...

Patients with some cancers, autoimmune diseases, and metabolic disorders often endure time-consuming intravenous (IV) infusions to receive the best protein-based treatments available. Because these ...

Intravenous (IV) injection is a common route for medical treatment worldwide as it induces rapid effects and allows continuous administration of medication by directly injecting drugs into the blood ...

“Niagen IV is now offered at over 900 clinics nationwide, including the new iCRYO locations,” stated Rob Fried, CEO of Niagen Bioscience. “This milestone highlights the growing recognition of Niagen ...

Panelists discuss how chronic kidney disease leads to iron deficiency anemia through a complex interplay of impaired iron absorption, increased hepcidin production driven by inflammatory cytokines, ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Unlike conventional techniques that require puncturing a lymph node or inserting a catheter (B, C), the lymphatic system can ...

Add Yahoo as a preferred source to see more of our stories on Google. Bioengineers in South Korea have succeeded in developing an intravenous needle (IV) that can bend and flex as it enters the human ...

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance ...